RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+11.17%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.93B
AUM Growth
+$3.93B
(-2.9%)
Cap. Flow
-$151M
Cap. Flow
% of AUM
-3.83%
Top 10 Holdings %
Top 10 Hldgs %
32.87%
Holding
120
New
16
Increased
40
Reduced
11
Closed
6
Top Buys
| 1 |
Surgery Partners
SGRY
|
$29.4M |
| 2 |
Eli Lilly
LLY
|
$26.3M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$23.4M |
| 4 |
Viking Therapeutics
VKTX
|
$21.4M |
| 5 |
Oscar Health
OSCR
|
$20.4M |
Top Sells
Sector Composition
| 1 | Healthcare | 96.88% |
| 2 | Consumer Staples | 1.95% |
| 3 | Industrials | 0.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $237M | 6.02% | 2,498,448 -383,119 | -13% | -$36.3M |
|
2
Immunocore
IMCR
$1.62B
| $154M | 3.91% | 2,367,816 -293,691 | -11% | -$19.1M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $145M | 3.69% | 1,054,900 -141,100 | -12% | -$19.5M |
|
4
Evolent Health
EVH
$1.12B
| $131M | 3.32% | 3,987,500 +27,500 | +0.7% | +$902K |
|
5
Intuitive Surgical
ISRG
$170B
| $119M | 3.02% | 298,500 | – | – |
|
6
UnitedHealth
UNH
$281B
| $114M | 2.89% | 230,000 | – | – |
|
7
Penumbra
PEN
$10.6B
| $113M | 2.86% | 505,000 -32,500 | -6% | -$7.25M |
|
8
Idexx Laboratories
IDXX
$51.8B
| $96.8M | 2.46% | 179,250 | – | – |
|
9
Acadia Healthcare
ACHC
$2.12B
| $93.3M | 2.37% | 1,177,500 +104,000 | +10% | +$8.24M |
|
10
argenx
ARGX
$43.6B
| $90.3M | 2.29% | 229,250 | – | – |
|
11
Boston Scientific
BSX
$156B
| $84.4M | 2.14% | 1,232,500 | – | – |
|
12
Ultragenyx Pharmaceutical
RARE
$2.89B
| $82.9M | 2.1% | 1,774,938 +20,900 | +1% | +$976K |
|
13
DexCom
DXCM
$29.5B
| $82.8M | 2.1% | 596,750 +750 | +0.1% | +$104K |
|
|
14
Eli Lilly
LLY
$657B
| $80.3M | 2.04% | 103,250 +33,750 | +49% | +$26.3M |
|
15
Freshpet
FRPT
$2.72B
| $76.8M | 1.95% | 662,500 | – | – |
|
|
16
Madrigal Pharmaceuticals
MDGL
$9.76B
| $76.4M | 1.94% | 285,931 +87,762 | +44% | +$23.4M |
|
17
Exact Sciences
EXAS
$8.98B
| $73.2M | 1.86% | 1,059,750 +40,250 | +4% | +$2.78M |
|
18
Align Technology
ALGN
$10.3B
| $72.1M | 1.83% | 220,000 | – | – |
|
19
Rhythm Pharmaceuticals
RYTM
$6.85B
| $66M | 1.68% | 1,522,893 | – | – |
|
20
Edwards Lifesciences
EW
$47.8B
| $61.9M | 1.57% | 647,300 | – | – |
|
21
Kymera Therapeutics
KYMR
$2.95B
| $61.2M | 1.55% | 1,522,238 | – | – |
|
22
Celldex Therapeutics
CLDX
$1.47B
| $57.6M | 1.46% | 1,372,185 +402,539 | +42% | +$16.9M |
|
23
Phreesia
PHR
$1.88B
| $56.6M | 1.44% | 2,365,000 +158,300 | +7% | +$3.79M |
|
24
Insulet
PODD
$23.9B
| $54.8M | 1.39% | 320,000 -111,750 | -26% | -$19.2M |
|
25
West Pharmaceutical
WST
$17.8B
| $54.3M | 1.38% | 137,250 | – | – |
|